TY - JOUR
T1 - Toward the development of a core set of outcome domains to assess shared decision-making interventions in rheumatology : results from an OMERACT Delphi survey and consensus meeting
AU - Toupin-April, Karine
AU - Barton, Jennifer
AU - Fraenkel, Liana
AU - Li, Linda C.
AU - Brooks, Peter
AU - Wit, Maarten De
AU - Stacey, Dawn
AU - Légaré, France
AU - Meara, Alexa
AU - Shea, Beverley
AU - Lyddiatt, Anne
AU - Hofstetter, Cathie
AU - Gossec, Laure
AU - Christensen, Robin
AU - Scholte-Voshaar, Marieke
AU - Suarez-Almazor, Maria E.
AU - Boonen, Annelies
AU - Meade, Tanya
AU - March, Lyn
AU - Pohl, Christoph
AU - Jull, Janet Elizabeth
AU - Sivarajah, Sigogini
AU - Campbell, Willemina
AU - Alten, Rieke
AU - Karuranga, Suvi
AU - Morgan, Esi
AU - Kaufman, Jessica
AU - Hill, Sophie
AU - Maxwell, Lara J.
AU - Welch, Vivian
AU - Beaton, Dorcas
AU - El-Miedany, Yasser
AU - Tugwell, Peter S.
PY - 2017
Y1 - 2017
N2 - Objective. The aim of this Outcome Measures in Rheumatology (OMERACT) Working Group was to determine the core set of outcome domains and subdomains for measuring the effectiveness of shared decision-making (SDM) interventions in rheumatology clinical trials.Methods. Following the OMERACT Filter 2.0, and based on a previous literature review of SDM outcome domains and a nominal group process at OMERACT 2014, (1) an online Delphi survey was conducted to gather feedback on the draft core set and refine its domains and subdomains, and (2) a workshop was held at the OMERACT 2016 meeting to gain consensus on the draft core set. Results.A total of 170 participants completed Round 1 of the Delphi survey, and 116 completed Round 2. Respondents came from 29 countries, with 49% being patients/caregivers. Results showed that 14 out of the 17 subdomains within the 7 domains exceeded the 70% criterion (endorsement ranged from 83% to 100% of respondents). At OMERACT 2016, only 8% of the 96 attendees were patients/caregivers. Despite initial votes of support in breakout groups, there was insufficient comfort about the conceptualization of these 7 domains and 17 subdomains for these to be endorsed at OMERACT 2016 (endorsement ranged from 17% to 68% of participants). Conclusion. Differences between the Delphi survey and consensus meeting may be explained by the manner in which the outcomes were presented, variations in participant characteristics, and the context of voting. Further efforts are needed to address the limited understanding of SDM and its outcomes among OMERACT participants.
AB - Objective. The aim of this Outcome Measures in Rheumatology (OMERACT) Working Group was to determine the core set of outcome domains and subdomains for measuring the effectiveness of shared decision-making (SDM) interventions in rheumatology clinical trials.Methods. Following the OMERACT Filter 2.0, and based on a previous literature review of SDM outcome domains and a nominal group process at OMERACT 2014, (1) an online Delphi survey was conducted to gather feedback on the draft core set and refine its domains and subdomains, and (2) a workshop was held at the OMERACT 2016 meeting to gain consensus on the draft core set. Results.A total of 170 participants completed Round 1 of the Delphi survey, and 116 completed Round 2. Respondents came from 29 countries, with 49% being patients/caregivers. Results showed that 14 out of the 17 subdomains within the 7 domains exceeded the 70% criterion (endorsement ranged from 83% to 100% of respondents). At OMERACT 2016, only 8% of the 96 attendees were patients/caregivers. Despite initial votes of support in breakout groups, there was insufficient comfort about the conceptualization of these 7 domains and 17 subdomains for these to be endorsed at OMERACT 2016 (endorsement ranged from 17% to 68% of participants). Conclusion. Differences between the Delphi survey and consensus meeting may be explained by the manner in which the outcomes were presented, variations in participant characteristics, and the context of voting. Further efforts are needed to address the limited understanding of SDM and its outcomes among OMERACT participants.
KW - clinical trials
KW - decision, making
KW - rheumatology
UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:45560
U2 - 10.3899/jrheum.161241
DO - 10.3899/jrheum.161241
M3 - Article
SN - 0315-162X
VL - 44
SP - 1544
EP - 1550
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 10
ER -